{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-LX84LEAY/88d5e96e-0b55-4e0c-ae78-e912dcb4bd18/HTML","dcterms:extent":"24 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-LX84LEAY/d68d4a8d-2ebc-4fae-b279-9daaeb872a31/PDF","dcterms:extent":"63 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-LX84LEAY/21a47a39-bce7-4c38-b931-a43d351846cd/TEXT","dcterms:extent":"14 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-LX84LEAY","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2008","dc:creator":"Žegura, Branka","dc:format":[{"@xml:lang":"sl","#text":"številka:3"},{"@xml:lang":"sl","#text":"3 strani"},{"@xml:lang":"sl","#text":"letnik:77"},{"@xml:lang":"sl","#text":"str. III-29-III-31"}],"dc:identifier":["ISSN:1318-0347","COBISSID:25007577","URN:URN:NBN:SI:doc-LX84LEAY"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"en","#text":"Endometrial Hyperplasia"},{"@xml:lang":"en","#text":"Endometrial Neoplasms"},{"@xml:lang":"sl","#text":"endometrij"},{"@xml:lang":"sl","#text":"Endometrij, hiperplazija"},{"@xml:lang":"sl","#text":"Endometrij, novotvorbe"},{"@xml:lang":"sl","#text":"Estrogeni"},{"@xml:lang":"en","#text":"Estrogens"},{"@xml:lang":"en","#text":"Hormone Replacement Therapy"},{"@xml:lang":"sl","#text":"Hormonsko nadomestno zdravljenje"},{"@xml:lang":"sl","#text":"rodila"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Endometrij in hormonsko nadomestno zdravljenje| Endometrium and hormonal replacement therapy|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. Estrogen induces endometrial stimulation and increases the risk for endometrial hyperplasia and endometrial cancer. Added progestin diminishes endometrial stimulation. The risk for endometrial hyperplasia with hormonal replacement therapy (HRT) depends of the type of formulation. Unopposed estrogen increases the risk of abnormal uterine bleeding, endometrial hyperplasia and carcinoma in a dose and time dependent manner. When progestin was added for 10 or more days, no endometrial hyperplasia has been seen with sequential HRT. No increased risk for endometrial hyperplasia has been found with continuous combined regimens. During the first year of HRT irregular bleeding and spotting was more likely in continuous combined therapy than in sequential therapy. Howerever, during the second year of the therapy it was more likely under sequential regimens. Conclusions. Only women after hysterectomy can use unopposed estrogen"},{"@xml:lang":"sl","#text":"Izhodišča. Estrogen sproži stimulacijo endometrija in poveča tveganje za hiperplazijo endometrija in karcinom endometrija. Estrogenu dodan progestagen preprečuje stimulacijo endometrija. Tveganje za hiperplazijo endometrija ob hormonskem nadomestnem zdravljenju (HNZ) je odvisno od vrste uporabljenega preparata. Monoterapija z estrogeni je dovoljena le pri ženskah po histerektomiji, saj estrogen v odvisnosti od trajanja zdravljenja in odmerka poveča tveganje za nenormalne krvavitve iz maternice, hiperplazijo in karcinom endometrija. Pri sekvencijskem HNZ do hiperplazije endometrija ne pride, če se mesečno za 10 dni ali več doda progestagen. Kombinirano HNZ ne povzroča hiperplazije endometrija. v prvem letu HNZ je več nenormalnih krvavitev iz maternice pri kontinuiranem kombiniranem HNZ; v drugem letu pa pri sekvencijskem HNZ. Zaključki. Zaradi varnosti endometrija je potrebno ženskam, ki imajo maternico predpisati kombinirano HNZ"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-LX84LEAY","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-LX84LEAY"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-LX84LEAY/d68d4a8d-2ebc-4fae-b279-9daaeb872a31/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-LX84LEAY/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-LX84LEAY"}}}}